Chronic illness affects 40 percent of school-aged children. Learn how caregivers can help reduce the stress and depression ...

Ask scientists which gene-editing tool is most needed to advance gene therapy, and they'd probably describe a system that's ...

Find out if gene therapy has also find its way into skin diseases. With two approvals in the last 2 years, is it the start of ...

22."A friend's brother-in-law was dying of cancer when, near the end, he got very excited and said, 'He's here! He's here! He ...

The gene editor -- called evoCAST -- goes a long way toward solving a problem that has confounded the development of gene therapies from the field's beginnings: How to add long stretches of DNA to ...

Biopharmas have been scaling back on AAV research for sometime now. Find out why and what's on the horizon for drug delivery ...

Novo has a strong balance sheet and ended 2024 with about DKK 26 billion in cash and marketable securities and DKK 103 billion of debt (following the acquisition of Catalent manufacturing sites in ...

When you visit the pharmacy, for example, those claims are adjudicated ... Add in inflation and new pharmaceutical drugs for conditions such as hemophilia, which can require ongoing specialty ...

Often misunderstood and surrounded by myths, hemophilia is far more complex than ... interacting with (for example, to limit the number of times an ad is presented to you). Information about ...

For example, with Eli Lilly and Company ... The FDA's recent approval of Qfitlia as a prophylaxis for patients with hemophilia A and B irrespective of inhibitors underpins a significant milestone ...

BioMarin agreed to shell out approximately $270 million for Inozyme Pharma, a developer whose treatments target the PPi-adenosine pathway, a key regulator of bone health and blood vessel function.